摘要：Enhanced intellectual property rules are noted as among the forces limiting the global access to medicines. In the European Union (EU), it is the Border Measures Regulation that has caused major disruptions for generic medicines in transit at its borders in the past. However, the Commission’s recent proposal for changes to the EU trademark rules promises another layer of restraint on access. In adopting the proposal, the European Parliament has moved to correct this syndrome by suggesting amendments that balance intellectual property and public health interest. But, can that pass the influence of corporate lobbyist? This essay argues that for the sake of certainty, the European Parliament’s amendments are good law and should be maintained.
关键词：Intellectual property rights; Access to medicines; EU trademark rules; Border measures; European Parliament; Article
